Previous 10 | Next 10 |
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic ...
DICE Therapeutics press release ( NASDAQ: DICE ): Q3 GAAP EPS of -$0.55 beats by $0.05 . Cash, cash equivalents and marketable securities totaled $266.6 million at September 30, 2022. In addition, in October 2022, DICE announced the successful closing of an upsized...
Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis Demonstrated direct inhibition of a cytokine with a small molecule in psoriasis patients, which we believe vali...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...
Summary DICE Therapeutics is a recent IPO. Recently, it came out with positive data from its lead asset. There are many hurdles to cross, but they have crossed the first hurdle quite convincingly. DICE Therapeutics ( DICE ) is a small molecule therapeutic develop...
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...
Biopharmaceutical company DICE Therapeutics ( NASDAQ: DICE ) has priced its upsized offering of 8,219,178 shares of its common stock at $36.50/share. Underwriters have been granted a 30-day option to purchase up to an additional 1,232,876 shares of its common stock at the ...
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...
News, Short Squeeze, Breakout and More Instantly...
DICE Therapeutics Inc. Company Name:
DICE Stock Symbol:
NASDAQ Market:
DICE Therapeutics Inc. Website:
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...